Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial

Peter W. Collins, Guy Young, Karin Knobe, +10

Blood

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B

Claude Négrier, Karin Knobe, Andreas Tiede, +2

Blood

Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

Andreas Tiede, B. Brand, R. Fischer, +5

Journal of Thrombosis and Haemostasis

PharmacologyHematologyRecombinant Factor ViiiHemostasisCoagulopathy +4

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

Annette von Drygalski, Pratima Chowdary, Roshni Kulkarni, +12

New England Journal of Medicine

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

Jais Rose Bjelke, Lene Hansen, Lars C. Petersen, +18

Blood

Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9‐GP), a glycoPEGylated recombinant factor IX

Peter W. Collins, Karin Knobe, Andreas Groth, +2

Journal of Thrombosis and Haemostasis

Pharmacokinetic ModelingPharmacologyPopulation Pharmacokinetic ModelingPharmacotherapyDose Setting +5

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

Johnny Mahlangu, Karin Weldingh, Steven R. Lentz, +38

Journal of Thrombosis and Haemostasis

Clinical ImmunologyMolecular ImmunologyImmunogeneticsVatreptacog AlfaAllergy +7

Factor VIII Inhibitors in Two Families with Mild Haemophilia A: Structural Analysis of the Mutations

Karin Knobe, Bruno O. Villoutreix, Lilian Tengborn, +2

Pathophysiology of Haemostasis and Thrombosis

ImmunogeneticsAutoimmune DiseaseFamily ClusterMild Haemophilia APathogenesis +12

Probing the activation of protein C by the thrombin-thrombomodulin complex using structural analysis, site-directed mutagenesis, and computer modeling

Karin Knobe, Ann Berntsdotter, Lei Shen, +3

Proteins Structure Function and Bioinformatics

Why does the mutation <i>G17736A</i>/Val107Val (silent) in the <i>F9</i> gene cause mild haemophilia B in five Swedish families?

Karin Knobe, Elsy Sjörin, Rolf Ljung

Haemophilia